{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:06:15Z","timestamp":1794344775365,"version":"4.9.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N93019C00052"],"award-info":[{"award-number":["75N93019C00052"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","award":["SRA-001"],"award-info":[{"award-number":["SRA-001"]}],"id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008065","name":"Georgia Research Alliance","doi-asserted-by":"publisher","award":["GRA-001"],"award-info":[{"award-number":["GRA-001"]}],"id":[{"id":"10.13039\/100008065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>While vaccines remain the best tool for preventing influenza virus infections, they have demonstrated low to moderate effectiveness in recent years. Seasonal influenza vaccines typically consist of wild-type influenza A and B viruses that are limited in their ability to elicit protective immune responses against co-circulating influenza virus variant strains. Improved influenza virus vaccines need to elicit protective immune responses against multiple influenza virus drift variants within each season. Broadly reactive vaccine candidates potentially provide a solution to this problem, but their efficacy may begin to wane as influenza viruses naturally mutate through processes that mediates drift. Thus, it is necessary to develop a method that commercial vaccine manufacturers can use to update broadly reactive vaccine antigens to better protect against future and currently circulating viral variants. Building upon the COBRA technology, nine next-generation H3N2 influenza hemagglutinin (HA) vaccines were designed using a next generation algorithm and design methodology. These next-generation broadly reactive COBRA H3 HA vaccines were superior to wild-type HA vaccines at eliciting antibodies with high HAI activity against a panel of historical and co-circulating H3N2 influenza viruses isolated over the last 15\u00a0years, as well as the ability to neutralize future emerging H3N2 isolates.<\/jats:p>","DOI":"10.1038\/s41598-020-79590-7","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T11:04:56Z","timestamp":1614683096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Next generation methodology for updating HA vaccines against emerging human seasonal influenza A(H3N2) viruses"],"prefix":"10.1038","volume":"11","author":[{"given":"James D.","family":"Allen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted M.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"key":"79590_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-020-0626-6","volume":"27","author":"J-R Chen","year":"2020","unstructured":"Chen, J.-R., Liu, Y.-M., Tseng, Y.-C. & Ma, C. Better influenza vaccines: an industry perspective. J. Biomed. Sci. 27, 1\u201311 (2020).","journal-title":"J. Biomed. Sci."},{"key":"79590_CR2","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","volume":"391","author":"AD Iuliano","year":"2018","unstructured":"Iuliano, A. D. et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 391, 1285\u20131300 (2018).","journal-title":"Lancet"},{"key":"79590_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/v8040096","volume":"8","author":"SV Vemula","year":"2016","unstructured":"Vemula, S. V. et al. Current approaches for diagnosis of influenza virus infections in humans. Viruses 8, 96 (2016).","journal-title":"Viruses"},{"key":"79590_CR4","doi-asserted-by":"publisher","first-page":"634","DOI":"10.15585\/mmwr.mm6722a4","volume":"67","author":"R Garten","year":"2018","unstructured":"Garten, R. et al. Update: influenza activity in the United States during the 2017\u201318 season and composition of the 2018\u201319 influenza vaccine. Morb. Mortal. Wkly. Rep. 67, 634 (2018).","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"79590_CR5","first-page":"558577","volume":"16","author":"L Castro","year":"2019","unstructured":"Castro, L., Bedford, T. & Meyers, L. J. B. Early prediction of antigenic transitions for influenza A H3N2. PLoS Comput. Biol. 16, 558577 (2019).","journal-title":"PLoS Comput. Biol."},{"key":"79590_CR6","doi-asserted-by":"crossref","unstructured":"McLean, H. Q. & Belongia, E. A. Influenza vaccine effectiveness: new insights and challenges. Cold Spring Harbor Perspect. Med., a038315 (2020).","DOI":"10.1101\/cshperspect.a038315"},{"key":"79590_CR7","first-page":"1845","volume":"69","author":"JR Chung","year":"2020","unstructured":"Chung, J. R. et al. Effects of influenza vaccination in the United States during the 2018\u20132019 influenza season. Clin. Infect. Dis. 69, 1845\u20131853 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"79590_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/infdis\/jiz543","volume":"221","author":"B Flannery","year":"2020","unstructured":"Flannery, B. et al. Spread of antigenically drifted influenza A (H3N2) viruses and vaccine effectiveness in the United States during the 2018\u20132019 season. J. Infect. Dis. 221, 8\u201315 (2020).","journal-title":"J. Infect. Dis."},{"key":"79590_CR9","doi-asserted-by":"publisher","first-page":"100054","DOI":"10.1016\/j.jvacx.2020.100054","volume":"4","author":"MM Loiacono","year":"2020","unstructured":"Loiacono, M. M. et al. Patient and practice level factors associated with seasonal influenza vaccine uptake among at-risk adults in England, 2011 to 2016: an age-stratified retrospective cohort study. Vaccine X 4, 100054\u2013100054. https:\/\/doi.org\/10.1016\/j.jvacx.2020.100054 (2020).","journal-title":"Vaccine X"},{"key":"79590_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa160","author":"JD Doyle","year":"2020","unstructured":"Doyle, J. D. et al. Relative and absolute effectiveness of high-dose and standard-dose influenza vaccine against influenza-related hospitalization among older adults\u2014United States, 2015\u20132017. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa160 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"79590_CR11","doi-asserted-by":"publisher","first-page":"Doc04","DOI":"10.3205\/id000030","volume":"5","author":"S Duwe","year":"2017","unstructured":"Duwe, S. Influenza viruses\u2014antiviral therapy and resistance. GMS Infect. Dis. 5, Doc04. https:\/\/doi.org\/10.3205\/id000030 (2017).","journal-title":"GMS Infect. Dis."},{"key":"79590_CR12","first-page":"1311","volume":"14","author":"M Bosaeed","year":"2018","unstructured":"Bosaeed, M. & Kumar, D. J. Seasonal influenza vaccine in immunocompromised persons. H. V. & Immunother. 14, 1311\u20131322 (2018).","journal-title":"H. V. & Immunother."},{"key":"79590_CR13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1042\/BST20180602","volume":"47","author":"ZB Reneer","year":"2019","unstructured":"Reneer, Z. B. & Ross, T. M. H2 influenza viruses: designing vaccines against future H2 pandemics. Biochem. Soc. Trans. 47, 251\u2013264. https:\/\/doi.org\/10.1042\/BST20180602 (2019).","journal-title":"Biochem. Soc. Trans."},{"key":"79590_CR14","doi-asserted-by":"publisher","first-page":"36216","DOI":"10.1038\/srep36216","volume":"6","author":"IV Alymova","year":"2016","unstructured":"Alymova, I. V. et al. Glycosylation changes in the globular head of H3N2 influenza hemagglutinin modulate receptor binding without affecting virus virulence. Sci. Rep. 6, 36216 (2016).","journal-title":"Sci. Rep."},{"key":"79590_CR15","first-page":"820","volume":"77","author":"WJ Dowdle","year":"1999","unstructured":"Dowdle, W. J. Influenza A virus recycling revisited. Bull. WHO 77, 820 (1999).","journal-title":"Bull. WHO"},{"key":"79590_CR16","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.3390\/ijms18081650","volume":"18","author":"W Shao","year":"2017","unstructured":"Shao, W., Li, X., Goraya, M. U., Wang, S. & Chen, J.-L. Evolution of influenza A virus by mutation and re-assortment. Int. J. Mol. Sci. 18, 1650 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"79590_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/irv.12447","volume":"11","author":"Y Lin","year":"2017","unstructured":"Lin, Y. et al. The characteristics and antigenic properties of recently emerged subclade 3C. 3a and 3C. 2a human influenza A (H3N2) viruses passaged in MDCK cells. Influenza Other Resp. Viruses 11, 263\u2013274 (2017).","journal-title":"Influenza Other Resp. Viruses"},{"key":"79590_CR18","doi-asserted-by":"crossref","unstructured":"Wei, C.-J. et al. Next-generation influenza vaccines: opportunities and challenges. Nat. Rev. Drug Discov. 19, 239\u2013252 (2020).","DOI":"10.1038\/s41573-019-0056-x"},{"key":"79590_CR19","doi-asserted-by":"publisher","first-page":"e00946","DOI":"10.1128\/JVI.00946-18","volume":"93","author":"JD Allen","year":"2019","unstructured":"Allen, J. D., Jang, H., DiNapoli, J., Kleanthous, H. & Ross, T. M. Elicitation of protective antibodies against 20 years of future H3N2 cocirculating influenza virus variants in ferrets preimmune to historical H3N2 influenza viruses. J. Virol. 93, e00946-e1918 (2019).","journal-title":"J. Virol."},{"key":"79590_CR20","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1016\/j.vaccine.2011.01.100","volume":"29","author":"BM Giles","year":"2011","unstructured":"Giles, B. M. & Ross, T. M. J. V. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine 29, 3043\u20133054 (2011).","journal-title":"Vaccine"},{"key":"79590_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1128\/CVI.05533-11","volume":"19","author":"BM Giles","year":"2012","unstructured":"Giles, B. M., Bissel, S. J., DeAlmeida, D. R., Wiley, C. A. & Ross, T. M. Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin. Vaccine Immunol. 19, 128\u2013139 (2012).","journal-title":"Clin. Vaccine Immunol."},{"key":"79590_CR22","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1093\/infdis\/jis232","volume":"205","author":"BM Giles","year":"2012","unstructured":"Giles, B. M. et al. A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J. Infect. Dis. 205, 1562\u20131570 (2012).","journal-title":"J. Infect. Dis."},{"key":"79590_CR23","first-page":"572","volume":"11","author":"CJ Crevar","year":"2015","unstructured":"Crevar, C. J., Carter, D. M., Lee, K. Y. & Ross, T. M. J. Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades. H. V. & Immunother. 11, 572\u2013583 (2015).","journal-title":"H. V. & Immunother."},{"key":"79590_CR24","doi-asserted-by":"publisher","first-page":"e01581","DOI":"10.1128\/JVI.01581-17","volume":"91","author":"TM Wong","year":"2017","unstructured":"Wong, T. M. et al. Computationally optimized broadly reactive hemagglutinin elicits hemagglutination inhibition antibodies against a panel of H3N2 influenza virus cocirculating variants. J. Virol. 91, e01581-e11517 (2017).","journal-title":"J. Virol."},{"key":"79590_CR25","doi-asserted-by":"publisher","first-page":"e01217","DOI":"10.1128\/JVI.01283-17","volume":"91","author":"DM Carter","year":"2017","unstructured":"Carter, D. M. et al. Elicitation of protective antibodies against a broad panel of H1N1 viruses in ferrets preimmune to historical H1N1 influenza viruses. J. Virol. 91, e01217\u2013e01283 (2017).","journal-title":"J. Virol."},{"key":"79590_CR26","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1128\/JVI.03152-15","volume":"90","author":"DM Carter","year":"2016","unstructured":"Carter, D. M. et al. Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses. J. Virol. 90, 4720\u20134734 (2016).","journal-title":"J. Virol."},{"key":"79590_CR27","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1128\/JVI.02257-12","volume":"87","author":"DM Carter","year":"2013","unstructured":"Carter, D. M. et al. Sequential seasonal H1N1 influenza virus infections protect ferrets against novel 2009 H1N1 influenza virus. J. Virol. 87, 1400\u20131410 (2013).","journal-title":"J. Virol."},{"key":"79590_CR28","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1128\/JVI.02372-15","volume":"90","author":"GA Kirchenbaum","year":"2016","unstructured":"Kirchenbaum, G. A., Carter, D. M. & Ross, T. M. Sequential infection in ferrets with antigenically distinct seasonal H1N1 influenza viruses boosts hemagglutinin stalk-specific antibodies. J. Virol. 90, 1116\u20131128 (2016).","journal-title":"J. Virol."},{"key":"79590_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.coi.2014.02.005","volume":"28","author":"GA Kirchenbaum","year":"2014","unstructured":"Kirchenbaum, G. A. & Ross, T. M. Eliciting broadly protective antibody responses against influenza. Curr. Opin. Immunol. 28, 71\u201376 (2014).","journal-title":"Curr. Opin. Immunol."},{"key":"79590_CR30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.coviro.2020.02.003","volume":"40","author":"J Ostrowsky","year":"2020","unstructured":"Ostrowsky, J. et al. Tracking progress in universal influenza vaccine development. Curr. Opin. Virol. 40, 28\u201336 (2020).","journal-title":"Curr. Opin. Virol."},{"key":"79590_CR31","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1089\/hum.2018.102","volume":"29","author":"ST Elliott","year":"2018","unstructured":"Elliott, S. T. et al. A synthetic micro-consensus DNA vaccine generates comprehensive influenza A H3N2 immunity and protects mice against lethal challenge by multiple H3N2 viruses. Hum. Gene Ther. 29, 1044\u20131055 (2018).","journal-title":"Hum. Gene Ther."},{"key":"79590_CR32","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1128\/JVI.02163-13","volume":"88","author":"KB Westgeest","year":"2014","unstructured":"Westgeest, K. B. et al. Genomewide analysis of reassortment and evolution of human influenza A (H3N2) viruses circulating between 1968 and 2011. J. Virol. 88, 2844\u20132857 (2014).","journal-title":"J. Virol."},{"key":"79590_CR33","doi-asserted-by":"crossref","unstructured":"Choi, A., Garc\u00eda-Sastre, A. & Schotsaert, M. Host immune response-inspired development of the influenza vaccine. Ann. Allergy Asthma Immunol. 125(1):28\u201335 (2020).","DOI":"10.1016\/j.anai.2020.04.008"},{"key":"79590_CR34","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1080\/21645515.2017.1423152","volume":"14","author":"JK Agor","year":"2018","unstructured":"Agor, J. K. & \u00d6zalt\u0131n, O. Y. Models for predicting the evolution of influenza to inform vaccine strain selection. Hum. Vaccines Immunother. 14, 678\u2013683 (2018).","journal-title":"Hum. Vaccines Immunother."},{"key":"79590_CR35","first-page":"1357","volume":"11","author":"BC Buckland","year":"2015","unstructured":"Buckland, B. C. The development and manufacture of influenza vaccines. H. V. Immunother. 11, 1357\u20131360 (2015).","journal-title":"H. V. Immunother."},{"key":"79590_CR36","doi-asserted-by":"publisher","first-page":"375","DOI":"10.4049\/jimmunol.1900379","volume":"204","author":"GA Sautto","year":"2020","unstructured":"Sautto, G. A. et al. A computationally optimized broadly reactive antigen subtype-specific influenza vaccine strategy elicits unique potent broadly neutralizing antibodies against hemagglutinin. J. Immunol. 204, 375\u2013385 (2020).","journal-title":"J. Immunol."},{"key":"79590_CR37","doi-asserted-by":"crossref","unstructured":"Kubo, M. & Miyauchi, K. Breadth of antibody responses during influenza virus infection and vaccination. Trends Immunol. 41(5):394\u2013405 (2020).","DOI":"10.1016\/j.it.2020.03.005"},{"key":"79590_CR38","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.coviro.2017.03.002","volume":"24","author":"D Corti","year":"2017","unstructured":"Corti, D. et al. Tackling influenza with broadly neutralizing antibodies. Curr. Opin. Virol. 24, 60\u201369 (2017).","journal-title":"Curr. Opin. Virol."},{"key":"79590_CR39","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1128\/JCM.43.6.3027-3029.2005","volume":"43","author":"F Ansaldi","year":"2005","unstructured":"Ansaldi, F. et al. New A\/H3N2 influenza variant: a small genetic evolution but a heavy burden on the Italian population during the 2004\u20132005 season. J. Clin. Microbiol. 43, 3027\u20133029 (2005).","journal-title":"J. Clin. Microbiol."},{"key":"79590_CR40","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1099\/jgv.0.001101","volume":"99","author":"K Beer","year":"2018","unstructured":"Beer, K. et al. Characterization of neutralizing epitopes in antigenic site B of recently circulating influenza A (H3N2) viruses. J. Gen. Virol. 99, 1001 (2018).","journal-title":"J. Gen. Virol."},{"key":"79590_CR41","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.it.2017.08.003","volume":"39","author":"C Henry","year":"2018","unstructured":"Henry, C., Palm, A.-K.E., Krammer, F. & Wilson, P. C. From original antigenic sin to the universal influenza virus vaccine. Trends Immunol. 39, 70\u201379 (2018).","journal-title":"Trends Immunol."},{"key":"79590_CR42","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1146\/annurev.iy.08.040190.003513","volume":"8","author":"IA Wilson","year":"1990","unstructured":"Wilson, I. A. & Cox, N. J. Structural basis of immune recognition of influenza virus hemagglutinin. Annu. Rev. Immunol. 8, 737\u2013787 (1990).","journal-title":"Annu. Rev. Immunol."},{"key":"79590_CR43","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/77802","volume":"1","author":"TM Ross","year":"2000","unstructured":"Ross, T. M., Xu, Y., Bright, R. A. & Robinson, H. L. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat. Immunol. 1, 127 (2000).","journal-title":"Nat. Immunol."},{"key":"79590_CR44","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1128\/JVI.77.3.2046-2055.2003","volume":"77","author":"TD Green","year":"2003","unstructured":"Green, T. D., Montefiori, D. C. & Ross, T. M. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J. Virol. 77, 2046\u20132055 (2003).","journal-title":"J. Virol."},{"key":"79590_CR45","doi-asserted-by":"publisher","first-page":"13580","DOI":"10.1128\/JVI.02289-14","volume":"88","author":"GS Tan","year":"2014","unstructured":"Tan, G. S. et al. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J. Virol. 88, 13580\u201313592 (2014).","journal-title":"J. Virol."},{"key":"79590_CR46","volume-title":"WHO Global Influenza Surveillance Network: Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza","author":"World Health Organization, G., Switzerland","year":"2011","unstructured":"World Health Organization, G., Switzerland. WHO Global Influenza Surveillance Network: Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza (World Health Organization, Geneva, 2011)."},{"key":"79590_CR47","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1586\/eri.11.51","volume":"9","author":"JM Katz","year":"2011","unstructured":"Katz, J. M., Hancock, K. & Xu, X. J. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Exp. Rev. Anti-infect Ther. 9, 669\u2013683 (2011).","journal-title":"Exp. Rev. Anti-infect Ther."},{"key":"79590_CR48","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1128\/JCM.00398-08","volume":"46","author":"DY Oh","year":"2008","unstructured":"Oh, D. Y., Barr, I. G., Mosse, J. A. & Laurie, K. L. MDCK-SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J. Clin. Microbiol. 46, 2189\u20132194 (2008).","journal-title":"J. Clin. Microbiol."},{"key":"79590_CR49","first-page":"1","volume":"44","author":"EMA, CHMP, VWP, 457259, C. f. M. P. f. H. U.","year":"2014","unstructured":"EMA, CHMP, VWP, 457259, C. f. M. P. f. H. U. Guideline on influenza vaccines. Non-clinical and Clinical module. Eur. Med. Agency 44, 1\u201331 (2014).","journal-title":"Eur. Med. Agency"},{"key":"79590_CR50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jviromet.2011.10.003","volume":"179","author":"K Sullivan","year":"2012","unstructured":"Sullivan, K. et al. High throughput virus plaque quantitation using a flatbed scanner. J. Virol. Methods 179, 81\u201389 (2012).","journal-title":"J. Virol. Methods"},{"key":"79590_CR51","doi-asserted-by":"crossref","unstructured":"Lin, Y., Gu, Y. & McCauley, J. W. Optimization of a quantitative micro-neutralization assay. J. Vis. Exps (JoVE) (2016).","DOI":"10.3791\/54897"},{"key":"79590_CR52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1743-422X-3-63","volume":"3","author":"M Matrosovich","year":"2006","unstructured":"Matrosovich, M., Matrosovich, T., Garten, W. & Klenk, H.-D. New low-viscosity overlay medium for viral plaque assays. J. Virol. 3, 63 (2006).","journal-title":"J. Virol."},{"key":"79590_CR53","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1128\/jcm.23.2.240-245.1986","volume":"23","author":"HH Walls","year":"1986","unstructured":"Walls, H. H., Harmon, M. W., Slagle, J. J., Stocksdale, C. & Kendal, A. P. J. Characterization and evaluation of monoclonal antibodies developed for typing influenza A and influenza B viruses. J. Clin. Microbiol. 23, 240\u2013245 (1986).","journal-title":"J. Clin. Microbiol."},{"key":"79590_CR54","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.vaccine.2016.11.060","volume":"35","author":"CA van Baalen","year":"2017","unstructured":"van Baalen, C. A. et al. ViroSpot microneutralization assay for antigenic characterization of human influenza viruses. Vaccine 35, 46\u201352 (2017).","journal-title":"Vaccine"},{"key":"79590_CR55","doi-asserted-by":"publisher","first-page":"W465","DOI":"10.1093\/nar\/gkn180","volume":"36","author":"A Dereeper","year":"2008","unstructured":"Dereeper, A. et al. Phylogeny. fr: robust phylogenetic analysis for the non-specialist. Nucleic Acids Res. 36, W465\u2013W469 (2008).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79590-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79590-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79590-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T12:11:33Z","timestamp":1674994293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-79590-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["79590"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-79590-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,2]]},"assertion":[{"value":"27 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4554"}}